Phastar nabs AstraZeneca, CRUK veteran as data science lead

Jennifer Bradford will lead Phastar's data science team. (Phastar)

U.S.-London CRO Phastar has hired Jennifer Bradford, Ph.D., to lead its data science group.

Phastar, like an increasing number of CROs, is looking to get the best out of clinical trials, and it sees artificial intelligence (AI) and machine learning (ML) as two of the best ways of doing this.

Bradford will now lead its team of AI and ML scientists in its relatively new data science group as the company hopes to cash in on the trendy analytics that could open up new opportunities in drug development.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

She comes to the biopharma services provider from a diverse background, working at AstraZeneca for nearly eight years and moving up to become its principle informatics scientist, working on advanced analytics for the U.K.-based Big Pharma.

After that stint, she moved to Cancer Research UK, the London-based cancer charity and research group, as senior clinical informatician at its Manchester Institute.

RELATED: CRO Phastar pens tech deal with newly bought out Medidata

“Jennifer brings a deep knowledge and breadth of experience to PHASTAR,” said Kevin Kane, CEO and founder of Phastar.

“The increasing complexity of clinical trial data can bring the most value when advanced techniques are applied that can identify data sources and associated analytics to answer key questions throughout the trial period. With the leadership that Jennifer brings to Phastar, the Data Science Group combined with other Phastar resources, can make a significant difference in the efficacy of clinical trials.”

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.